Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(13)
DRUG(2)
RADIATION(2)
PROCEDURE(1)
Laboratory Biomarker Analysis
3 trials
early_phase_1not_applicablephase_1_2
mayo-clinic
rituximab
2 trials
phase_1_2
national-cancer-institute-nci, mayo-clinic
Questionnaire Administration
2 trials
early_phase_1not_applicable
mayo-clinic
Single Photon Emission Computed Tomography
1 trial
phase_1_2
mayo-clinic
Quality-of-Life Assessment
1 trial
not_applicable
mayo-clinic
yttrium Y 90 ibritumomab tiuxetan
1 trial
phase_1_2
national-cancer-institute-nci
Yttrium Y-90 Ibritumomab Tiuxetan
1 trial
phase_1_2
mayo-clinic
Agatolimod Sodium
1 trial
phase_1_2
mayo-clinic

+7 more interventions

15 unique interventions5 categories

Analytics

Trial Phases

Phase 12
Phase 22

Trial Status

Completed3
Terminated1

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT02652715Not ApplicableCompleted
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-Cell LymphomaAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma+29 more
PrincipalinvestigatorStart date: 2016-01-19
NCT01719250Early Phase 1Completed
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma+2 more
PrincipalinvestigatorStart date: 2012-12-01
NCT00012298Phase 1/2Terminated
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+6 more
Principalinvestigator
NCT00438880Phase 1/2Completed
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone Lymphoma+9 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Marginal Zone Lymphoma+16 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Lymphoma, Large-Cell, AnaplasticAngioimmunoblastic T-cell LymphomaLymphoma, Large B-Cell, Diffuse+7 more

Worked with same sponsors:

Mayo ClinicNational Cancer Institute (NCI)
Similarity Score7%

Steven Horwitz, MD

Memorial Sloan Kettering Cancer Center

Related
7 trials

Shared therapeutic areas:

Adult T-Cell Leukemia/LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell Lymphoma+6 more
Similarity Score6%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Lymphoma, Mantle-CellRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseWaldenstrom Macroglobulinemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score1%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score1%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Recurrent Mantle Cell LymphomaWaldenstrom Macroglobulinemia
Similarity Score1%

Carlos Montalbán Sanz, MD

Hospital Universitario Ramon y Cajal

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT02652715Not ApplicablePrincipalInvestigator

Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

Adult Nasal Type Extranodal NK/T-Cell LymphomaAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma+29 more
Completed
NCT01719250Early Phase 1PrincipalInvestigator

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma+2 more
Completed
NCT00012298Phase 1/2PrincipalInvestigator

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+6 more
Terminated
NCT00438880Phase 1/2PrincipalInvestigator

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Adult Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone Lymphoma+9 more
Completed

All 4 trials loaded